“(2) Condition A is that the expenditure is attributable to relevant research and development undertaken on behalf of the company. … (4) Condition C is that the expenditure is not incurred by the company in carrying on activities which are contracted out to the company by any person. (5) Condition D is that the expenditure is not subsidised (see section 1138).”
“See sections 1124, 1126 and 1132 for provision about when particular kinds of expenditure are attributable to relevant research and development”
“2. The payment to undertake the research work will be expensed for accounts purposes (and consequently be tax deductible) when incurred because it could not be said with sufficient certainty that the prepayment would have value to the LLP. 3. By virtue ofsection 118ZA Income and Corporation Taxes Act 1988 , the results of the LLP are attributed to the corporate. 4. By virtue ofsection 118ZC Income and Corporation Taxes Act 1988 , the loss that is available to the corporate to offset is not restricted to amount [sic] of its capital because it remains liable to contribute to the partnership after the end of the relevant accounting period (see section 118ZC(4)). 5. The LLP gets relief for expenditure, including subcontracted research and development (see paragraph 3(3)(d) schedule 20Finance Act 2000 ). 6. Paragraph 12 [of schedule 20] provides that 65% of the payment is eligible for research and development labs. Paragraph 13 provides that the relief is 175% of the amount. Therefore, for every£100 spent by the LLP, the tax-deductible expense is (£100 x 65% x 175% + 35%)=£148.75 .”
“If the expenditure [by the company or LLP as the case may be] is research and development expenditure which is not capital expenditure, then it may qualify for an uplift of 30% under the provisions of schedule 12Finance Act 2002 (if it is a large enterprise) or 75% schedule 20Finance Act 2000 (if it is a micro, small or medium sized enterprise)…. [The definition of qualifying R&D expenditure in paragraph 3 of schedule 20 is set out] …Broadly speaking, the above provisions apply to research and development expenditure carried on by employees, by persons provided by third parties, or by work that is subcontracted. In the case of work that is subcontracted only 65% of the amount of the payment is eligible for the uplift (unless the subsidiary and the subcontractor jointly elect that the expenditure of the subsidiary is only deductible to the extent it is matched by payments by the subcontractor and the conditions in paragraph 10(1)(b) Schedule 20Finance Act 2000 are satisfied). The effect of this would be that 148.75%, rather than 175%, of the expenditure would be deductible for tax purposes.” [The definition of qualifying R&D expenditure in paragraph 3 of schedule 20 is set out] (5) It appears from e-mails sent on19 March 2009 by Mr Timol that a OneE strategy meeting was to be held at head office on 1 April, and that one of the items was for Mr Slattery to give a 90 minute technical overview on IR 35 and Ultra Green to “advisers”
“As Royal Assent gets closer, notwithstanding my recent e-mail of keeping Lazarus operational alongside TGI, it is dawning on me that we have to get the TGI side in order urgently. I therefore had a chat with Dom on Friday and have listed the 4 key areas we need to create a workable investment offering in…”
“At present these are very much draft as I have to: 1. Proof read 2. Add to the Case Law, Ramsay and GAAR points 3. Consolidate questions to counsel In the mean time [sic] if you could read, add the bit in CAPS / highlighted and make any changes you deem appropriate.”
“How will the price of £X be arrived at? Specifically will this be arrived at by a real negotiation between parties acting at arm’s length, or by reference to a formula, or by reference to criteria pre-established?”
“Based on current deal flow, I would imagine we can generate circa£20M of direct investments monies annually God willing into Tax Geared Investments. … 1. We are planning on offering a ‘double play’ consisting of pharma via Nemaura and building Kempinski hotels via Taurus Finance who we both met with Dom a few months ago. As such deal flow will be shared between the two offerings. 2. Our offering are seasonal. Hence we want to push this in the two month window leading up to the Chancellors Autumn Statement in Nov and then in the new year in the run up to the budget normally delivered in March. Legislative uncertainty precludes us planning beyond these two timeframes…”
“I enjoyed our chat yesterday. I will be in London Monday and Tuesday of next week and I will probably also be in London Monday and Tuesday of the following week (16th and 17th). It would be great to meet up if that were possible. I look forward to taking you through where I am on the structure at the moment.”
“I really enjoyed meeting you last week and I look forward to meeting up again in the future to discuss possibilities. I am also really keen in examining the “Irish option”
“to further explore Joshua as a potential solution for Irish companies. In this regard, if you would be so kind as to sign an NDA (Anne to provide) then Tim (copied) will furnish you with further details (including the counsel opinion via lock lizard) regarding Joshua. With regards the R&D planning, I think I now understand the logic, my main concern was deal flow; both in terms of R&D and external funding. You mentioned that you are in touch with some Switz firms who have very large capacity as well as Trinity College Dublin who may have some capacity. Could you please furnish me with further information in this regard with a view to discussing further in the new year followed by a meeting with these chaps. I am keen to progress matters and there appears to be a good fit between our two firms.”
“Further to Dom’s e-mail below you should have now received our standard NDA via our electronic signature method of Docusign. Should you have any queries with this NDA please let me know. Otherwise, upon signature and return I will ask. Tim to organise the additional Joshua documentation. In terms of a follow up meeting, due to both Bashir and Dom taking holiday in January, the earliest I am able to offer is week commencing 3 February. However, this week does currently have good availability for them both. Would any day this week suit yourself for a meeting in either London or at our Head Office in Bolton?”
“Kieran has just reviewed the NDA and would appreciate if the agreement could cover information disclosed in both directions as he will be disclosing information regarding his clients in discussion. Would it be possible for you to make the necessary amendment and return it for signature?”
“I attach an amended NDA as requested. I will void the one we sent via DocuSign. Could you please ask Kieran to review and sign the attached NDA and then return to me initially by scan so we can release the additional information but also with the original to follow in the post? I will ensure signature at this end and a copy returned to you for your files.”
“INTRODUCTION (A) Each of the Parties to this Agreement (“the Parties”) would like to review certain of the other parties [sic] information so that the Parties may investigate a way to develop future products (the “Purpose”). This will necessitate the disclosure of information which each Party wishes to protect from unauthorised disclosure and use. IT IS AGREED between the Parties as follows: 1 Information disclosed to the Recipient under this Agreement will include, but not be limited to, tax planning solutions, commercial, financial, operational or other information in whatever form (including information disclosed orally) which concerns the Purpose or the business and affairs of the other Party and is of a confidential nature, including any such information disclosed prior to the date of this Agreement (“Confidential Information”). For the avoidance of doubt, Confidential Information shall include, but not be limited to, all and any analyses, compilations, studies or other documents prepared by the Recipient on the basis of or derived from or otherwise containing the Confidential Information (or any part of it) (“Derived Information”). 2 In consideration of the Parties agreeing to disclose the Confidential Information to each other, each Party (in its capacity as the Recipient) will: (a) keep in confidence any Confidential Information disclosed to it by the other Party and will not disclose that Confidential Information to any other person (other than, in accordance with clause 2(c), its employees who need to know the Confidential Information in order to carry out the Purpose) without the written consent of the other Party; (b) use the Confidential Information disclosed to it only for the Purpose; (c) ensure that all employees (or persons for whom written consent has been obtained in accordance with clause 2(a)) to whom the Confidential Information is disclosed by the Recipient (directly or indirectly) under this Agreement are aware of the terms of this Agreement and shall be responsible to the other Party for any breaches by them of any of the terms of this Agreement; (d) keep all Confidential Information in a safe and secure place; and (e) not make copies of the Confidential Information without the prior written consent of the other Party. 3 The Recipient will keep the existence, nature and content of this Agreement confidential, together with the fact that work is taking place concerning the Purpose. Any information developed as a result of the Purpose shall also constitute Confidential Information for the purposes of this Agreement. 4 Clauses 2 and 3 will not apply to: (a) information which has been published other than through a breach of this Agreement; (b) information which the Recipient can prove was lawfully in its possession before its disclosure under this Agreement took place; (c) information which the Recipient can prove was obtained from a third Party who was free to disclose it; (d) information which the Recipient can prove was independently developed by it; (e) information which the Recipient is required by law (including a regulatory body) to disclose PROVIDED THAT the Recipient has, if it ins lawful to do so, given notice to the other Party of any such actual or anticipated requirement promptly upon becoming aware of it and used reasonable endeavours or co-operate with the other Party regarding timing and content of such disclosure or any action which the other Party may reasonably elect to take to challenge the validity of such requirement; and (f) information which the other Party agrees in writing that the Recipient may disclose.”
“I am attaching a draft set of instructions in advance of our meeting on Thursday. When we meet tomorrow we can discuss them in greater detail and I can complete the draft following our discussions. You will note that there are certain issues that will require some further detailed discussion. Obviously until the structure of the investment is decided upon, we will not have available detailed legal documentation for your review.”
“Counsel is asked to advise on a range of taxation issues involving an investment structure which would enable UK corporate investors to invest in a range of projects requiring significant research and development financing. It is intended to make the structure accessible to companies in the United Kingdom in a manner that they would be in a position to take advantage of the relief provided for in Part 13 of Chapter 4 of theCorporation Tax Act 2009 in relation to the additional tax relief that is provided therein for expenditure on research and development. The legislation deals with different situations where R&D relief can be granted and, in particular, distinguishes between ‘large companies’ and ‘SMEs’ in this regard. However, the structure envisages that the UK investor companies would qualify as SMEs within the meaning of the legislation and not as large companies. Accordingly the “Chapter 2” provisions in the legislation which deal with SMEs are the provisions relevant to these instructions.”
“1. That UK corporate investors would be entitled to claim a share of the loss arising in the LLP against the total profits for the relevant corporates. HMRC have issued a guideline, CIRD81220- R&D tax relief: conditions to be satisfied: company as member of partnership, which indicates that this would in face be the position. 2. Counsel is asked to advise as to whether or not the loss could be carried back against a previous accounting period. It would appear that this would not be possible in respect of a s1045 loss unless additional R&D relief was claimed in that previous accounting period (see s1048(2)). However, a trading loss under 1044 would appear to be capable of being so carried back, provided the company carried on a similar trade in that period. 3. Given the fact that investors would have an entitlement to a genuine commercial upside in the investment and taking into account that the investors would be asked to subscribe by way of capital in the region of 35% of the total expenditure of the LLP, with the promoter investor lending 65% of the total expenditure of the LLP, that the recently introduced general anti-avoidance rules (GAAR) in the UK would not apply to the transaction in question. If it is considered that GAAR may have application, what key commercial criteria should attach to the transaction to minimise the risk of GAAR application. 4. A structure may also be considered that would allow the relevant UK investor company contributing a higher percentage as their capital contribution to the project in return for a higher share of profit participation on the exploitation of the project. 5. Would the making of a non-recourse loan by the promoter might carry implications for tax purposes that would not arise if the technology promoter actually invested capital in the partnership. 6. What would be the potential implications of the promoter facilitating the non-recourse loan being made to the LLP by a third party financial group? 7. What would be the apportionment rules that would apply in relation to apportioning a part of the loss of the LLP against the profits of the accounting period of the relevant corporate? 8. Any other issues that arise out of this structure that may occur to counsel and could have taxation implications for the promoter investor or the relevant corporate investors.”
“Section 1136- Unconnected parties- ‘the 65% rule’ Section 1136 deals with a situation where the contractor and the subcontractor are not connected and do not elect to be connected. Section 1136(2) provides that; “the qualifying element of the subcontractor payment is 65% of the subcontractor payment”
“Hi Kieran, I hope you are keeping well and apologise for the delay in reverting back to you. Further to our meeting, I have now reviewed the instructions and have the following notes / comments: 1. Virtually all of our clients are SMEs and so there would be very wide appeal for this type of company. 2. What is the LLP solvency / legal position of having losses that are way in excess of the LLP capital. Have you considered or taken advice on this point? 3. I believe the same restriction in s.59/s.60 CTA 2010 will apply to this type of LLP and therefore the members would need to remain liable to contributed [sic] additional assets on a winding up. Can you confirm is this is correct [sic] and what the extent of the liability will be? 4. Trading point. When will the trade commence? What will the timeframes be for expenditure by the sub-contractors? This could make the number of closings easier to manage. 5. Also re trading, the monitoring / management of the LLP is usually key to this- what is envisaged to ensure this is done? 6. I note you have laid out your interpretation of the legislation and asked counsel for comment. Have you received the counsel’s opinion now (or do you have a timeframe for the same)? Would you be willing for us to review this once it is available? Perhaps a call on this would be best? If so please advise of a good time to call. I also said I would come back to you on the key practical / procedural points that need to be considered for this to work for us. These are: 1. We would require monthly closes (or at least every other month) to take into account company year ends. This may result in difficulties, particularly from a cash-flow perspective of the R&D companies. 2. Provided the LLP is trading then the amount of the relief would be£180k for each£100k of LLP expenditure. We discussed that the LLP would loan£75k and the corporates put in£25k . This would result in a loss of£180k for the LLP fully relievable for the corporate members. At 20% CT this is spending£25k to save£36k . We discussed this was the right ratio for us in terms of a balancing point for what clients would be willing to invest. However, if there is a risk that the LLP is not trading, the relief would be restricted to 65% of£225k =£146k . At 20% this would mean£30k tax relief for a£20k investment. An investment somewhere between 20-25% might be best to cover this risk. It would depend on how counsel advises on the trading point and the other areas of interpretation, as to how big we feel the risk is. 3. The management fees / other expenses will need to be covered only where the LLP has funds. 4. Regulatory points: this is a UCIS (Kieran to confirm?) and hence we would need to promote carefully and only to the correct people. From your point of view, I think the action points were: 1. Obtain additional and revised term sheets from the various companies / investment houses you have been liaising with. Have you had further meetings / progress in this regard? 2. Revert on how you see us best working together. As we discussed in the meeting we hold the internal resource and expertise from similar structures we are currently operating. 3. As above, hopefully you have now had the chance to review the documentation / opinion on Joshua? Please do let me know if you have any questions or would like to discuss. If you are free for a call to go through this I am relatively free today / tomorrow so please let me know.”
“Apologies for the missed calls on Friday. I spoke to Tim today who tells me you spoke on Friday. He mentioned you were still waiting for Sherry. Did you still need to discuss any updates with me? From recollection you were: 1. Looking into the Joshua docs 2. Speaking with the R&D companies 3. Finalising with Sherry We were to: 1. Review your instructions to Sherry- done Was there anything else?”
“Dear Tim, Following our conversation today, I attach a business plan for Morvus which is a biotech company which intends to go the AIM stock market in London by the end of this year or certainly very early in 2015. … The structure that we discussed on the phone would be that the new LLP would undertake say£3million worth of research which would be spent on qualifying research expenditure within the meaning of the R&D legislation. This would meant that the LLP would elect to be connected to a company with which it would subcontract the research would probably be a new subsidiary of Morvus and therefore all of the expenditure would qualify for the full 225% relief. This would obviate the subcontracting issues that were discussed in the memorandum I submitted to counsel. As part of the commercial arrangements between the LLP and Morvus, the£3million would be regarded as a loan to Morvus… A variation on the structure is that we agree a deal with an underwriter via a stockbroker in London to underwrite the purchase of the loan note in, say, two years time via a put option or a put / call option….I am meeting with two stockbroking firms in London next week to discuss this possibility. … I am also developing a structure to raise a larger R&D fund within an LLP to invest in a range of companies coming to market, either here or in the United States over the course of the next year. It would then mean that the investors would be able to cross-collateralise their investment in the LLP through a range of projects. It would only require one of these projects to be a flotation success for them to reduce their risk very considerably. If we can attach the underwriting arrangement to it, it would be a very robust structure indeed. As I say, I will be London during the course of next week, meeting with Morvus and the stockbroking firms and I would be interested in your initial response to this idea.”
“Hi Dom, As discussed I have listed some items that I would put on the backburner for the time being: 1. Instructing on s.175A planning 2. Kieran Corrigan stuff 3. S.131 schemes 4. Drip drop / EBT Extraction 5. Pension solution 6. Joshua / Extraction with Marc Ainscough 7. School fees Planning”
“- KC outline of structure with [redacted] - [redacted] - If 225% relief, split should be 1/3 to 2/3 - If 65% rule: split should be 25% to 75% - LLP structure for R&D investments (ex: Morvus) … - Main query: is the structure impacted by GAAR or DOTAS? Key is if the primary objective is the investment in Bio Tech and NOT the tax advantage. … - KC to send MS confirmation of final structure from [redacted] - Comprehensive view on the commercial arrangements … - [redacted] - If 225% relief, split should be 1/3 to 2/3 - If 65% rule: split should be 25% to 75% - Comprehensive view on the commercial arrangements - MS proposes potential partner in [redacted] - MS will set up an introduction, if we can prepare a presentation to be sent to them”
“Further to your meeting with Dom he has asked if you are kindly able to forward the further information about Pre-IPO? ….”
“As the roadshow will commence with ZAI next week, this is now a straight issue for shares as opposed to the convertible loan note we originally discussed. There can be no differential in the funds being raised concurrently, as I am sure you appreciate. The£1m being raised through the R&D LLP structure will be subject to the enhanced tax relief of 225% which gives a tax benefit of 47.25%. We strongly believe this is an attractive proposition for One E to pursue and look forward to discussing it with you in further detail.”
“TJ / Adam, As you are aware, I have be wen [sic] speaking with Kieran RE potential planning ideas surrounding R&D reliefs. Some are purely investment based with enhanced tax benefits given the RD credits) and some are to be both enhanced investments AND geared. The attached is pure investment based with enhanced relief only (no gearing)- Can you please conduct some DD on the attached p provided Kieran confirms the opportunity is still available. Kieran, please confirm where you are with Sherry opinion, Joshua DD & talks with the Swiss investors?”
“TJ, I have very quickly put these instructions together. I have not even proof read them yet but thought I’d get them out to you guys ASAP. Can you please review and pay close attention to the tax analysis.”
“Hi Dom, You said you were sending through a revised version of this. I should get round to reviewing this afternoon so will you be sending the revised doc and should I wait for it until reviewing?”
“Hi Dom, See attached with my notes on the instructions. I was going to go through these with Adam but didn’t get chance before his holiday.”
“- The corporates are entitled to 100% of the 181.25% relief, provided - The LLP is trading and R&D valued correct: - all money is spent or will be spent regardless of success, - the R&D qualifies as R&D under the Guidelines, - the LLP’s sub-contractor payment is deductible under GAAP, - qualifies as a sub-contractor payment under s 1133(1) CTA 2009 and - relief not prevented by s. 1084 CTA 2009 or case law”
“Last sentence of 139- not sure why this is relevant as the LLP and subco are not connected hence there is no need to consider 1124 etc? (falls under 1136- not connected hence 65% but don’t need to consider 1124 etc.)”
“Last sentence of paragraph 139- not sure why this is relevant as the LLP and subco are not connected hence there is no need to consider 1124 etc? (falls under 1136- not connected hence 65% but don’t need to consider 1124 etc.) 16. These provisions are relevant in determining whether expenditure is qualifying expenditure on contracted out R&D for the purposes of section 1053. 17. Although the fact that the companies are connected is relevant to the calculation of the qualifying element of a sub-contractor payment (section 1053(1)(a) and 1036 CTA 2009) there is an additional requirement that expenditure is “attributable to relevant research and development” in section 1053(2) CTA 2009. It is in determining whether this condition is satisfied that section 1124, 1126 and 1132 are relevant (see in this respect section 1053(6) CTA 2009). 18. I do not consider that the fact that the parties are connected obviates the need to show that expenditure is attributable to relevant research and development in order to satisfy the conditions in section 1053 CTA 2009.”
“A key component of our original instructions was that where the subcontractor payment was to an unconnected party, there is no need to ‘look through’ to the subcontractor to see whether the money is attributable to relevant R&D. The question is why anyone would not elect to be connected if the same obligation exists to spend the money on relevant R&D. I think the answer might be that we have to show that the LLP payment is attributable to relevant R&D, but the subcontractor does not have to demonstrate the same and also spend the money within a specific timeframe. I will look into this further before our meeting.”
“Further to our call, the point we need to get comfortable on is the importance of connection between the LLP and the subcontractor, and what expenditure of the LLP will qualify for enhanced R&D relief. The starting point is that we have based our previous discussion on the assumption that the LLP and subcontractor will not be connected. That is because we assumed that there would not be as high a threshold compared to when the LLP and subcontractor are connected. If the LLP and subcontractor are not connected As summarised in paragraphs 114 to 144 of your opinion, s.1044 gives relief for “Qualifying Chapter 2 Expenditure”
“Tim, Dom, Kieran Corrigan signed NDA attached. Please note this was amended from our standard NDA by Richard to cover exchange of information both ways.”
“Just looking at the attached, the recipient is described as Kieran Corrigan and so it is not very well drafted to cover exchange of information both ways. Is it worth getting Anne to see what exactly was agreed in the e-mails at the time. The trail below just says ‘as discussed’.”
“Dear Dominic, Further to our phone conversation last week, I had hoped that we would speak yesterday but I didn’t hear from you. I am very anxious to discuss the Nemaura structure with you as a matter of great urgency. I have been working flat out on this project for some months now and have just now finalised our own structure with Michael Sherry. As you will imagine, I am deeply concerned about the structure you are now marketing in the context of all of our discussions to date. Will you please let me know when it will be possible to have a call to discuss this. I will be tied up for most of this afternoon but I could speak to you later this morning or tomorrow morning.”
“Dear Dominic, I have to say, I remain deeply disappointed in what has occurred. I find it extraordinary that, under a confidentiality agreement, I would provide you with every piece of information, including my submission to Counsel and that you are not prepared to provide me with the structure that you are now marketing. I have reflected on the fact that you may have communicated with Michael Sherry. It is clear that this is really none of my business and none of my concern. What you discuss with Michael is a matter between yourself and Michael. The issue that arises is a matter between the members of your organisation and the members of my organisation in relation to information flows under the signed confidentiality agreement. I will obviously be taking advice on my situation and we shall see where we go from there.”
“It continues to frustrate me that (1) you seem to believe my company has done anything untoward when I have explained fully the situation and (2) that you continue to say that I am not prepared to show you our structure. I have confirmed both verbally and in writing that I am prepared to show you the details of our structure provided you do so at one of our offices without taking the information away with you.”
“- If the parties are unconnected, the enhanced R&D relief is 65% of the normal 125% - Where the parties are connected, the relief is not restricted however only expenditure on staff, software, consumables and externally provided workers will qualify. - It must also be spent by the sub-contractor within the relevant period- generally 2 months from the end of the accounting period in which the sub-contractor payment is made. - Where the parties are not connected the above restrictions will not apply.”
“- Does s.1053(6) gives [sic] provision for particular kinds of expenditure being attributable to relevant R&D. This means expenditure on staff, software and consumables must be carefully monitored, but a more general approach will be taken for all other expenditure, provided it qualifies as R&D.”
“The tax analysis relatively simple: the LLP obtains a current year loss as the tax treatment follows GAAP and Investor 2 [the corporate investor] can utilize this loss against its other profits (or carry back the loss 12 months, or carry forward the loss against profits of the same trade in future years). The question is whether any other factors could affect this analysis…”
“The basic attribute or quality which must be shown to attach to the information for it to be treated as confidential is inaccessibility: the information cannot be treated as confidential if it is common knowledge or generally accessible and in the public domain. Whether the information is so generally accessible is a question of degree depending on the particular case. It is not necessary for a claimant to show that no one else knew of or had access to the information.”
“…information which- (a) is secret in the sense that it is not, as a body or in the precise configuration and assembly of its components, generally known among, or readily accessible to, persons within the circles that normally deal with the kind of information in question, (b) has commercial value because it is secret, and (c) has been subject to reasonable steps under the circumstances, by the person lawfully in control of the information, to keep it secret”
“When the information is mixed, being partly public and partly private, then the recipient must take special care to use only the material which is in the public domain. He should go to the public source and get it: or at any rate, not be in a better position than if he had gone to the public source. He should not get a start over others by using the information which he received in confidence. At any rate, he should not get a start without paying for it.”
“It is not every derived product, process or business which should be treated as a camouflaged embodiment of the confidential information and not all ongoing exploitation of such products, processes or business should be treated as continued use of the information. It must be a matter of degree whether the extent and importance of the use of the confidential information is such that continued exploitation of the derived matter should be viewed as continued use of the information.”
“one could scarcely imagine a more correspondent set of remedies as damages for fraudulent breach of contract and equitable compensation for breach of fiduciary duty in relation to the same factual situation, namely the deliberate withholding of money due by a manager to his artist. It would have been a blot on our jurisprudence if those selfsame facts gave rise to a time bar in the common law courts but none in the court of equity.”